Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke | Zendy

Steven C. Cramer | Zendy; Bams Abila | Zendy; Nicola Scott | Zendy; Monica Simeoni | Zendy; Lori Enney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke

Author(s) -

Steven C. Cramer,

Bams Abila,

Nicola Scott,

Monica Simeoni,

Lori Enney

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.674366

Subject(s) - medicine , stroke (engine) , pharmacokinetics , placebo , tolerability , adverse effect , pharmacodynamics , clinical trial , anesthesia , pharmacology , pathology , mechanical engineering , alternative medicine , engineering

Restorative therapies have the potential to improve function and reduce disability after stroke with a wide therapeutic window. The current study evaluated GSK249320, a monoclonal antibody that blocks the axon outgrowth inhibition molecule myelin-associated glycoprotein and also protects oligodendrocytes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research